ReviewCureus2025
Tumor Microenvironment in Cancer Biology: A Comprehensive Review of Stromal, Immune, and Vascular Components Driving Malignancy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
- Multidimensional 5-hydroxymethylcytosine features in cell-free DNA enable the detection, staging and subtyping of pancreatic ductal adenocarcinoma.Biomarker research · 2026Article
- Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME), comprising the extracellular matrix (ECM), stromal cells, immune cells, and vascular components, plays a decisive role in cancer growth, metastasis, and treatment response. Although cancer research has traditionally focused on tumor cells, increasing evidence shows that the TME actively influences tumor behavior. This narrative review synthesizes recent findings on the stromal, immune, and vascular elements of the TME, drawing on advanced approaches such as single-cell RNA sequencing and AI-assisted imaging. Cancer-associated fibroblasts (CAFs) promote tumor progression through ECM remodeling and immune suppression, while vascular abnormalities limit drug delivery and contribute to therapeutic resistance. Emerging TME-targeted strategies, including anti-angiogenic agents, immune checkpoint inhibitors, and stromal-directed therapies, show promise but remain challenged by TME heterogeneity and tumor adaptability. The evidence indicates that targeting the TME represents a major shift in cancer therapy and offers important opportunities to develop more effective and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.